A retrospective review of dupilumab and psoriasis biologic combination therapy.

: Sometimes patients have more than one disease where different arms of the immune system are active necessitating multiple biologics at the same time. In this study, we report on experience with the use of dupilumab and psoriasis biologics in combination. : A retrospective chart review of patients on dupilumab and an FDA approved psoriasis biologic between January 1, 2016 and May 1, 2019 was performed. Seven patients met these criteria. : All seven patients completed combination dupilumab/guselkumab treatment for 2-13 months (mean =6.4, median =6). Improvement in AD or BP and psoriasis was observed in six out of the seven patients. No serious adverse effects were observed. : Although cost consideration and long-term monitoring to evaluate the true safety of biologic treatment used in combination are necessary, the benefits may outweigh the risks of using dupilumab with other biologics in combination in patients with these indications.